“Robin is a true business partner. He was instrumental during my recruitment process from day one. Not only did he take the time to guide me and hand hold me throughout the different steps, but he took the time to follow up on my wellbeing and my family’s wellbeing too. Robin is results and people oriented, and I would trust him to any other endeavours in the future! Thank you Robin, you made this easier for me, and if I had to do it again, I would ask for you! Kudos!”
HR Business Partner & Operations Lead – Canada & North America, Biocon
“Ewan is an absolute pleasure to work with. He is full of enthusiasm and very knowledgeable of industry hiring needs. Best interest of his clients seem to always be his priority, which is refreshing to see. He is a problem solver and ready to take lead, but also knows when to step back and let his clients take the lead. Along with Alessandro Mantell, they make a perfect team. Highly recommended.”
Business Development Head, Biocon
Biocon Limited, publicly listed in 2004, is India’s largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, they have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high.
Biocon has also built one of the largest and most diverse biosimilar pipelines, spanning insulins, monoclonal antibodies and other recombinant proteins that address critical chronic diseases such as diabetes, cancer and autoimmune disorders.
Ranked among the Top 3 biosimilar players globally for rh-insulin and insulin glargine in volume terms, they are the first Indian company to launch a biosimilar in Japan with Insulin Glargine, which also has been approved for sale in EU and Australia. Their insulin products have made a difference to the lives of millions of people with diabetes across the globe. They now aim to provide insulin products to ‘one in five’ people with diabetes in need of insulin-based therapy anywhere in the world within the next 10 years.
Company website – https://www.biocon.com/
To find out more about Biocon, contact Robin Mantell on +1 (786) 485 1298 or robin.mantell@mantellassociates.com.